News|Videos|February 5, 2024
Understanding Malignancy Risks With the Use of CAR T-cell Therapies
Author(s)Caron Jacobson, MD, Miguel-Angel Perales, MD
Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
Advertisement
Episodes in this series
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5